Key facts
- Demeter Bio’s last known valuation is $6.8M (Oct 2025).
- It has raised $1.5M; the latest was Early Stage VC ($1.5M) in Oct 2025.
- Notable investors include SyndicateRoom, One Planet Capital, Undaunted, Carbon13, biotope by VIB.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Demeter Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Demeter Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Demeter Bio
Developer of high-performance advanced materials designed to replace conventional, resource-intensive components across sectors. The company's platform integrates novel material formulations and scalable processing technologies to deliver enhanced mechanical, thermal, and functional properties, enabling manufacturers to improve product performance while reducing environmental impact.
- Sector
- Materials and Resources
- HQ
- London, United Kingdom
- Founded
- 2025
- Employees
- 3
- Website
- demeter-bio.com/
- Ownership
- Privately Held (backing)
Demeter Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Demeter Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Demeter Bio in its N-PORT filings yet. We sweep new filings monthly.